Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Early vs. deferred transplantation in AL amyloidosis

Surbhi Sidana • 1 Jun 2020
Amyloidosis Rare Diseases Antibodies Bortezomib Daratumumab

Surbhi Sidana, MD, Mayo Clinic, Stanford, CA, compares early versus deferred stem-cell transplantation for amyloid light-chain (AL) amyloidosis patients, as evaluated in a retrospective study comparing overall survival between patients who proceed directly to autologous stem cell transplant after stem cell collection and those who defer. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).

More from Surbhi Sidana

1:29
Managing toxicities associated with immunotherapy in multiple myeloma
Surbhi Sidana • 8 Dec 2023
1:43
Ide-cel therapy for multiple myeloma with renal impairment
Surbhi Sidana • 8 Dec 2023
3:09
An overview of the toxicities associated with immunotherapy in multiple myeloma
Surbhi Sidana • 8 Dec 2023
1:59
Real-world outcomes of ide-cel in heavily pre-treated R/R MM
Surbhi Sidana • 8 Dec 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals